1-15 of 366

KRAS G12C Biology: Why Is This Mutation Different?
MinuteCE®KRAS G12C Biology: Why Is This Mutation Different?

From Biopsy to Results: Building a Reflex-Ready Testing Workflow
MinuteCE®From Biopsy to Results: Building a Reflex-Ready Testing Workflow

The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
MinuteCE®The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?

Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
MinuteCE®Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
- advertisement

Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
MinuteCE®Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors

Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
MinuteCE®Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens

Beyond Steroids in Warm AIHA: A Practical Framework for Diagnosis, Relapse Management, and Emerging Therapies
CME/CEBeyond Steroids in Warm AIHA: A Practical Framework for Diagnosis, Relapse Management, and Emerging Therapies

What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
CME/CEWhat the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management

SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
CME/CESOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions

The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CEThe Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
- advertisement
CME/CE In-Person & Virtual EventSpotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders


































